open access

Vol 51, No 1 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-03-01
Submitted: 2019-06-03
Get Citation

VTD in comparison with VCD does not affect stem cell yields with G-CSF only mobilization

Matevz Skerget, Barbara Skopec, Matjaz Sever
DOI: 10.2478/ahp-2020-0009
·
Acta Haematol Pol 2020;51(1):42-46.

open access

Vol 51, No 1 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-03-01
Submitted: 2019-06-03

Abstract

Triplet induction regimens are standard of care for newly diagnosed transplant eligible multiple myeloma patients. The combinations of bortezomib and dexamethasone with either cyclophosphamide (VCD) or thalidomide (VTD) are widely used. There are no data available on the impact of the two regimens on stem cell harvest by using G-CSF only mobilization. In this study, we retrospectively analyzed data from our national registry. The outcome measures were mobilization failure, CD34+ cell counts on collection day, number of apheresis procedures, and the number of collected cells. Overall, 72 patients were treated with either VCD or VTD. The mobilization failure rates were 7% and 9% ( = 0.771) and the total number of collected stem cells were 7.0 × 10 and 6.7 × 10 per kg body weight ( = 0.710) for VCD and VTD, respectively. We found no statistically significant difference between the treatment groups in the outcome measures. The addition of thalidomide to bortezomib and dexamethasone (VTD) does not adversely affect stem cell harvest in patients mobilized with G-CSF only.

Abstract

Triplet induction regimens are standard of care for newly diagnosed transplant eligible multiple myeloma patients. The combinations of bortezomib and dexamethasone with either cyclophosphamide (VCD) or thalidomide (VTD) are widely used. There are no data available on the impact of the two regimens on stem cell harvest by using G-CSF only mobilization. In this study, we retrospectively analyzed data from our national registry. The outcome measures were mobilization failure, CD34+ cell counts on collection day, number of apheresis procedures, and the number of collected cells. Overall, 72 patients were treated with either VCD or VTD. The mobilization failure rates were 7% and 9% ( = 0.771) and the total number of collected stem cells were 7.0 × 10 and 6.7 × 10 per kg body weight ( = 0.710) for VCD and VTD, respectively. We found no statistically significant difference between the treatment groups in the outcome measures. The addition of thalidomide to bortezomib and dexamethasone (VTD) does not adversely affect stem cell harvest in patients mobilized with G-CSF only.

Get Citation

Keywords

myeloma; HSCT; stem cell transplantation; mobilization; G-CSF

About this article
Title

VTD in comparison with VCD does not affect stem cell yields with G-CSF only mobilization

Journal

Acta Haematologica Polonica

Issue

Vol 51, No 1 (2020)

Pages

42-46

Published online

2020-03-01

DOI

10.2478/ahp-2020-0009

Bibliographic record

Acta Haematol Pol 2020;51(1):42-46.

Keywords

myeloma
HSCT
stem cell transplantation
mobilization
G-CSF

Authors

Matevz Skerget
Barbara Skopec
Matjaz Sever

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl